The United States Patent and Trademark Office (USPTO) has published patent application US20260083848A1, titled 'CAR T-cell therapy combined with BTK inhibitors for cancer'. The application, filed on November 2, 2022, and published on March 26, 2026, discloses the use of engineered immune effector cells (like T-cells or NK cells) expressing a Chimeric Antigen Receptor (CAR) in combination with a kinase inhibitor, specifically a BTK inhibitor, for treating diseases such as hematological malignancies.

This publication is a patent application, not a rule or guidance, and therefore does not impose direct compliance obligations. However, it signifies a new disclosure in therapeutic approaches for cancer treatment. Companies involved in drug development, particularly in oncology and immunology, should be aware of this patent filing as it may relate to their research and development activities or intellectual property strategies. No immediate actions are required from a compliance perspective, but monitoring patent landscapes is crucial for R&D and IP departments.